You are here

Research as a Change Agent to Improve Care and Outcomes: The Kaiser Permanente Northern California Experience

Weekly Seminar | Not Open to the Public
Who Should Attend: 


Alan S. Go, M.D.
Regional Medical Director of Clinical Trials
Kaiser Permanente Northern California Division of Research
Associate Director
Cardiovascular and Metabolic Conditions Research
Kaiser Permanente Northern California Division of Research
Solutions through Technology and Advanced Analytics Research (STAR) Group
Kaiser Permanente Northern California Division of Research
Professor of Epidemiology, Biostatistics and Medicine
University of California at San Francisco
Consulting Professor of Medicine, Health Research and Policy
Stanford University


Improving population-level quality of care and clinical outcomes remains a daunting challenge nationally. Over the past 20 years, Dr. Go has developed an internationally-recognized research program within Kaiser Permanente Northern California, a large integrated healthcare delivery system providing comprehensive care for >4 million members that is supported by a state-of-the-art electronic health record system. His research program has expanded from an initial focus on the epidemiology of cardiovascular and kidney-related conditions to systematic evaluation of “real world” quality of care and associated outcomes to spearheading the development and implementation of system-wide efforts to improve the conduct of clinical trials and research studies. Through the strategic use of research in alignment with key clinical and operational stakeholders within complex healthcare delivery systems like Kaiser Permanente, Dr. Go and colleagues have helped create important infrastructure and processes that support the ability to accelerate large-scale change internally, as well as externally through successful multi-institutional collaborations.

Alan S. Go, M.D. Figure


Go AS, Reynolds K, Yang J, Gupta N, Lenane J, Sung SH, Harrison TN, Liu TI, Solomon MD.
Association of Burden of Atrial Fibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal Atrial Fibrillation: The KP-RHYTHM Study.
JAMA Cardiol. 2018 Jul 1;3(7):601-608. doi: 10.1001/jamacardio.2018.1176.
Go AS, Singer DE, Toh S, Cheetham TC, Reichman ME, Graham DJ, Southworth MR, Zhang R, Izem R, Goulding MR, Houstoun M, Mott K, Sung SH, Gagne JJ.
Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.
Ann Intern Med. 2017 Dec 19;167(12):845-854. doi: 10.7326/M16-1157. Epub 2017 Nov 14.
Rana JS, Tabada GH, Solomon MD, Lo JC, Jaffe MG, Sung SH, Ballantyne CM, Go AS.
Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population.
J Am Coll Cardiol. 2016 May 10;67(18):2118-2130. doi: 10.1016/j.jacc.2016.02.055.


Tuesday, February 12, 2019 - 12:30pm


785 Mamaroneck Avenue
White Plains, NY 10605
United States
Conference Room: 
Billings Building – Rosedale

More Information